Alendronate better than risedronate at increasing BMD

Article

Weekly treatment with alendronate is more effective in building bone in the hip and spine than weekly risedronate, according to a new head-to-head study of the drugs.

Weekly treatment with alendronate is more effective in building bone in the hip and spine than weekly risedronate, according to a new head-to-head study of the drugs. The findings were from a post-hoc analysis of FACT (Fosamax Actonel Comparator Trials), a double-blind, randomized trial of alendronate and risedronate. More than 1,000 postmenopausal women with and without osteoporosis were enrolled in the 12-month trial.

Weekly alendronate (70 mg) was significantly more effective in increasing hip trochanter, lumbar spine, and total hip bone mineral density (BMD), regardless of a patient's osteoporotic status. In women with osteoporosis, alendronate increased BMD by 3.6%, 3.6%, and 2.1% in those sites, respectively, compared with 2.0, 2.5, and 1.0 for risedronate (35 mg). The osteoporotic patients on alendronate also had greater decreases in biochemical markers indicative of their condition than did their counterparts taking risedronate. No significant differences were seen between the two treatments in adverse events, including upper gastrointestinal problems.

Bonnick S, Hochberg M, Broy S, et al. Comparison of once-weekly alendronate and once-weekly risedronate in the osteoporotic subgroup from the FACT study. Poster presented during the 6th International Symposium on Osteoporosis: Current Status and Future Directions in Washington, D.C.

Recent Videos
Expert discussions from the 2025 ACOG meeting | Image Credit: © stevengaertner - © stevengaertner - stock.adobe.com.
Trina Mansour, MD
Negative pressure wound therapy reduces c-section infections and costs | Image Credit: doctors.valleyhealth.com.
Amy Valent DO, MCR, highlights new tech for prenatal diabetes management | Image Credit: linkedin.com.
Lisa Bayer, MD, MPH
Megan Wasson, DO, FACOG
Megan Cohen, MD, MPH, outlines 2024 CDC contraception guidelines | Image Credit: linkedin.com.
Wasson and Colak
Johanna Finkle, MD, weight loss specialist, OB/GYN, The University of Kansas Health System.
Navigating hormone therapy in high-risk menopause cases | Image Credit: © dhaj7-cepo.com.
© 2025 MJH Life Sciences

All rights reserved.